

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference: 0073		APCBSSE/0073
Drug name and formulations:		Velphoro® - sucroferric oxyhydroxide
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Comparable GI side effects to other phosphate binding agents. Idiosyncratic responses.
Clinical effectiveness	<i>Established licensed product</i>	Velphoro® found to be non-inferior to sevelamer. Velphoro® may be a useful agent for the defined group of patients that can tolerate it.
Strength of evidence		RCT evidence presented - strong observational evidence with large patient numbers.
Cost effectiveness or resource impact	£	Cost of Velphoro® on par with lanthanum, more expensive than sevelamer.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	2 nd or 3 rd line agent. Sevelamer is 1 st line unless contra-indicated. Patient to have tried or found to be intolerant to sevelamer.
National guidance and priorities	<i>NICE, MTRAC</i>	SMC approved for use in Scotland In line with NICE guideline on phosphate binding agents.
Local health priorities	<i>CCG views</i>	CCGs supportive if used as described in application
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	Specialist use only. It was noted that sevelamer and lanthanum which are AMBER do not have ESCAs because they are well established, having been used for a long period of time; the need for an ESCA was withdrawn when the chapter was harmonised.

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	N/A
Not approved and rationale:	N/A
Formulary status (RAG) and rationale	RED status. <u>Rationale</u> : Small patient numbers anticipated. Patients expected to have regular contact with specialist. NHSE commissioned.
Implementation requirements:	N/A
Implementation monitoring:	N/A